Tempus AI, Inc. - Class A Common Stock (TEM)

Cathie Wood-led Ark Invest sold shares of Tempus AI, bought Bullish, Amazon, and Figma. The moves align with recent achievements and advancements of the companies.

The AI heathcare tech specialist is about to put another product on the market.

Tempus AI's Tempus Pixel received FDA clearance for cardiac imaging updates, adding T1/T2 maps to enhance MR image analysis and diagnosis precision.

Shares jumped into a profit-taking zone Thursday after the FDA cleared its updated cardiac-imaging platform.

Artificial intelligence is the hottest investing trend of 2025.

Revenue growth is soaring for TempusAI, and that has investors excited.

On Tuesday, Cathie Wood-led Ark Invest sold shares of Tempus AI Inc (NASDAQ: TEM) through ARK Genomic Revolution ETF (ARKG) and ARK Innovation ETF (ARKK) totaling $2.1 million. This follows Tempus AI's recent acquisition and mixed analyst ratings. Other key trades include purchases of Prime Medicine Inc (PRME) and Twist Bioscience Corp (TWST).

Tempus AI (TEM) excels with a perfect technical rating, accelerating revenue growth of 89.57%, and strong earnings momentum, fitting the high-growth Minervini Trend Template.

Bearish investors are hammering these three stocks with short selling. However, all three have promising developments on their side that bears may be missing.

The artificial intelligence revolution is leaving no opportunity unaddressed.

Tempus AI acquires Paige in an $81.25 million deal, adding FDA-cleared cancer detection tools and a dataset of 7 million pathology slides to enhance precision medicine.

High short interest will impact these stocks in Q3, but they are set up to move higher and hit new highs, driven by catalysts in Q4, including the Q3 results.

Cathie Wood-led Ark Invest made significant trades on Tuesday with notable activity in Bullish (NYSE:BLSH), Robinhood Markets Inc. (NASDAQ:HOOD), and Tempus AI Inc. (NASDAQ:

Cathie Wood's ARK Innovation ETF is outperforming tech market again in 2025, driven by AI breakthroughs and the return of inflows.

These 10 large-cap stocks gained this week, some due to positive news such as media rights deals or FDA approvals.

Donald Trump has accused Nancy Pelosi of trading on "inside information" after her portfolio's returns outperformed the S&P 500 in 2025.

Stocks continued to rise despite conflicting inflation data; the trend is still bullish, but investors should expect volatility heading into September